|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Exelixis, Inc.
210 East Grand Avenue
South San Francisco
California
94083-0511
U.S.A.
Phone:
650-837-7000
Fax:
650-837-8300
|
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo.
By investing in robust discovery and preclinical development infrastructure, the company has been able to bring very high quality compounds into the clinic in rapid fashion. Just four years after filing its first investigational new drug application (IND) to begin clinical trials of a proprietary compound, Exelixis has 14 compounds in clinical development and is positioned to build a leading franchise in cancer therapeutics.
A fundamental philosophy at Exelixis is the belief that advancing the treatment of cancer necessitates increased understanding of the disease itself. A key component of the company’s strategy is to gain insight into the complex molecular mechanisms that drive the growth, survival, and resistance of cancer cells, and utilize this knowledge to simplify, streamline, and inform the entire drug development process. This approach allows Exelixis to be both innovative and strategic while moving quickly in the right direction.
Recognizing that diverse molecular pathways impact the development, progression, spread, and survival of different cancer types, Exelixis is building a pipeline of compounds with unique target profiles. This approach allows the development of individual drug candidates for those cancer indications and patient populations where the pharmacology of the compound addresses the biology of the disease.
Exelixis’ ability to take this approach is a result of the company’s extensive expertise in pathway biology, and is supported by an integrated approach to discovery, translational medicine, and clinical development. Everyone at Exelixis believes that extensive discovery research isn’t just good science – it is also critical to good medicine. By understanding target biology and compound activity early on, Exelixis researchers seek to identify those patients most likely to benefit from a given drug candidate, and pursue a clearly defined path through the clinic and toward the market.
To support its robust and growing product pipeline, Exelixis is establishing a seamlessly integrated R&D organization with the critical mass to leverage data effectively and the flexibility to incorporate new insights into our strategies. The ability to make rational and data-driven decisions at each point along the drug development continuum strengthens the entire process. Extensive target characterization enhances the company’s ability to select indications and patient populations in which its drug candidates are most likely to provide benefit, and its experiences in the clinic help to identify additional areas of unmet medical need on which future discovery and development efforts can be focused.
Email:
info@exelixis.com
Ownership:
Public
Web Site:
Exelixis, Inc.
Employees:
450
Symbol: EXEL
|
|
|
Company News |
Exelixis, Inc. (EXEL) Announces Webcasts of Upcoming Investor Conference Presentations
6/6/2013 6:44:45 AM
More...
|
Exelixis, Inc. (EXEL) Presents COMETRIQ™ (cabozantinib) Clinical Trial Data in Patients With Progressive, Metastatic Medullary Thyroid Cancer
6/3/2013 11:02:21 AM
More...
|
Exelixis, Inc. (EXEL) Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men With Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
6/3/2013 10:42:59 AM
More...
|
Exelixis, Inc. (EXEL) Announces Webcasts of Upcoming Investor Conference Presentations
5/9/2013 7:33:05 AM
More...
|
Exelixis, Inc. (EXEL) Release: Cabozantinib to be Featured in Nine Presentations at the 2013 American Society of Clinical Oncology Annual Meeting
5/8/2013 7:51:51 AM
More...
|
Exelixis, Inc. (EXEL) Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call
4/18/2013 7:10:43 AM
More...
|
Preclinical Data Presented at American Association for Cancer Research Describe a Mechanism of Action of Exelixis, Inc. (EXEL)'s Cabozantinib in a Prostate Cancer Bone Metastasis Model
4/10/2013 6:46:28 AM
More...
|
Exelixis, Inc. (EXEL) Release: Preclinical Data Presented at American Association for Cancer Research Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis Model
4/10/2013 6:14:58 AM
More...
|
Exelixis, Inc. (EXEL) Announces Webcast of March 4 Presentation at the 33rd Annual Cowen and Company Health Care Conference
2/26/2013 6:43:04 AM
More...
|
Exelixis, Inc. (EXEL) Selects Swedish Orphan Biovitrum as COMETRIQ™ European Distributor for Medullary Thyroid Cancer
2/22/2013 10:08:51 AM
More...
|
|
|
|
 |
|
|
|
|
|
|